Aim. The aim of this study was to compare the quality of life after transcatheter aortic valve implantation (TAVI) and surgical replacement (SAVR) at one year. Methods. The study included 45 consecutive high-risk patients (average age 82.0 years; logistic Euroscore 22.3%) with symptomatic severe aortic stenosis allocated to TAVI transfemoral, TAVI transapical using the Edwards-Sapien valve or SAVR with the Edwards Perimount bioprosthesis (n=15 in each). The pre-operative characteristics were similar except for more myocardial infarctions in TAVI. The quality of life was assessed using the standardized EQ-5D questionnaire at baseline and on days 30, 90 and 360. The protocol was approved by the local ethics committee and an informed consent was signed. A total of 7 patients (15.5%) died during follow-up. Results. At baseline no significant differences in any of the quality-of-life parameters were found except for usual activities described as "best" (46.7% in SAVR vs. 10.0% in TAVI; P=0.002). At 30 and 90 days surviving patients were similar and at 360 days only the anxiety/depression score was "best" in 83.3% SAVR vs. 59.1% (P=0.046). Functional status improved in all patients (NYHA class I-II in 13.3% at baseline vs. 78.9% at 360-days) and the general health median significantly improved in TAVI patients (from 50 to 67; P=0.001) with a positive trend in SAVR patients (P=0.060). Conclusions. At one year, the general quality of life of high-risk patients had significantly improved after transcatheter aortic valve implantation with a positive trend in surgically treated patients.
INTRODUCTION
Surgical aortic valve replacement (SAVR) was, until recently, the only effective therapeutic option for patients with symptomatic aortic stenosis. Unfortunately one third of patients did not receive this treatment mainly because of advanced age or severe co-morbidities 1 . The main negative prognostic factors linked to short-term postoperative mortality were quantitatively determined from the logistic EuroScore which has been recently updated in the EuroScore II (www.euroscore.org) (ref. 2 ). However, even the new scoring system is unable to capture the complete risk of patients, for instance those with poor mental status, contraindication for general anesthesia, or extracorporeal circulation. In the PARTNER trial it was shown that patients who were not indicated for SAVR benefited from transcatheter aortic valve implantation (TAVI) (ref. 3 ). The balloon-expandable Sapien valve (Edwards Lifesciences, Inc., Irvine, California, United States) can be used for TAVI delivered through the transfemoral (TF) or transapical (TA) approach 4 , additionally, the self-expanding CoreValve system (Medtronic-CorevalveTM, LLC; Minneapolis, Minnesota, United States) is also commercially available. The aim of this study was to ascertain the quality of life of TAVI patients in the initial phase of the program directly compared with SAVR patients as the well-established method in the same center. When dealing with the elderly population at very high risk, the quality of life should be at least as important as survival 5 .
MATERIALS AND METHODS
The single-center observational study included 45 consecutive high-risk patients (average age 82.0 ± 4.5 years; logistic EuroSCORE 22.3 ± 7.6; diabetes mellitus 42.2%) with symptomatic severe aortic stenosis indicated for aortic valve intervention from June 2009 to December 2010 (68.9% were women). Patients age > 75 years with a logistic Euroscore > 15% were divided into one of three groups according to the type of procedure: TAVI transfemoral (TF-TAVI) (n=15), TAVI transapical (TA-TAVI) (n=15) or SAVR (n=15). All procedures were performed under general anesthesia and in cases of TF-TAVI a common femoral artery was surgically disected. The pre-operative characteristics were similar except for more frequent myocardial infarctions in the TAVI groups. The Edwards Sapien valve was implanted in the TAVI patients and Edwards Perimount bioprosthesis was used in the SAVR patients. The logistic Euroscore was significantly higher in the TAVI groups than in the SAVR group (18 vs. 24; P=0.025). The selection of patients was approved by the multidisciplinary heart-team according to the recommendation of Vahanian et al. 6 and all the characteristics, treatments and results are described in detail in a previous publication 7 . In summary, patients with a bicuspid aortic valve, ischemic heart disease requiring revascularization after the aortic valve intervention, severely impaired left ventricular ejection fraction and mitral or aortic regurgitation were contraindicated for the procedures. Also, patients with serious co-morbidities and an estimated life expectancy of less than three years were not enrolled. The patients were followed according to the protocol approved by the local ethics committee. All patients signed an informed consent before baseline investigations and the study was conducted in accordance with the Helsinki declaration. In addition to the more exact clinical, echocardiographic and CT angiographic parameters, we also measured subjective health status attributable to treatment. The quality of life was assessed using a self-administered standardized EuroQol EQ-5D questionnaire 8 describing mobility, self-care, usual activities, pain/discomfort, anxiety/depression and general health at baseline (D0), 30-days (D30), 90-days (D90) and 360-days (D360). Each dimension had three levels reflecting health problems as none -moderate -extreme. The current general health was determined by a mark placed on a 20-centimeter visual analog scale. Analysis was done in the "intention-to-treat" manner and all the EQ-5D data from baseline through the 1-year follow-up were obtained from 33 patients. The EQ-5D questionnaire was used with permission of the EuroQol Group.
Statistical analysis
Standard descriptive statistics were applied in the analysis. Quantitative variables were described using means and standard deviation or median supplemented by 5 th -95 th percentile range; categorical variables were described as absolute and relative frequencies. Direct comparison among groups was set up using the ML-Chi-square test for categorical variables and Mann-Whitney U test for quantitative variables. Changes in the EQ-5D dimensions between baseline and 1-year follow-up were analyzed using the Wilcoxon test. The level of statistical significance was set at α=0.05. All analyses were carried out with the software SPSS 19.0.1 (IBM Corporation, 2010).
RESULTS
The main clinical, echocardiographic and laboratory results were described previously 7 . Because of the obvious association between the objective and subjective parameters of health, it is necessary to briefly mention the results. All patients in all groups were treated successfully with either TAVI or SAVR. One patient suffered an iliac rupture at the end of the TF-TAVI, which was immediately surgically corrected in the hybrid operating theatre. Three patients had repeat procedures (1 SAVR and 2 TA-TAVI). There were several other complications, e.g. renal failure in six patients, respiratory failure in six patients and neurological complications in four patients. The functional status after the procedure and follow-up was significantly improved for the total group of surviving patients (New York Heart Association [NYHA] class I-II in 13.3% at baseline vs. 78.9% at 360-days and at the same time NYHA class IV decreased from 22.2% to 0%). All procedures were technically successful, 2 patients (4.4%) died during the 30-day or prolonged hospital stay and another 5 patients (11.1%) died during the 1-year follow-up.
The prognostic impact of the objective parameters and complications defined in the VARC (Valvular Academic Research Consortium) (ref. 9 ) are under investigation and will be published separately.
1. Comparison of TAVI vs. SAVR: At baseline no significant differences in overall quality-of-life parameters were found among groups except for usual activities described as "best" (46.7% in SAVR vs. 10.0% in TAVI; P=0.002). At 30 and 90 days the surviving patients reported a similar health status. At 360 days, only the anxiety/depression score described as "best" was found more often in SAVR patients (83.3% vs. 59.1%; P=0.046). General health significantly improved only in TAVI patients (P=0.001); however, there was a positive trend found in SAVR patients (P=0.060). (Table 1) 2. Comparison of TF-TAVI vs TA-TAVI vs SAVR: Very similar results in the quality of life assessment were found if the analysis was also focused on the type of TAVI approach. We observed one exception regarding the general health feeling of patients at 90 days. Patients treated with the TF-TAVI scored lower than SAVR patients but this difference had disappeared at one year. No differences were found between TF-and TA-TAVI patients over the course of the study. (Table 2) 
DISCUSSION
Our study focused on the quality of life (QoL) assessed by the standardized EQ-5D three level questionnaire in patients treated using the classical surgical approach (SAVR) compared with patients treated with TAVI. The general quality of life as well as all physical dimensions and NYHA functional status were similar at baseline but significantly improved one year after TAVI (general QoL 50 vs. 67 points for TAVI; NYHA III-IV in 86.6% vs. 21% in the whole group). These results correspond well with the results of Georgiadou P et al. 
CONCLUSIONS
Transcatheter aortic valve implantation (TAVI), even at the beginning of the program, was shown to be associated with excellent short-and middle-term results up to one year of follow-up. Relatively low mortality and excellent functional status of such patients has been well documented after both TAVI and surgical aortic valve replacement. At one year, the general quality of life of the surviving high-risk elderly patients was significantly improved after transcatheter aortic valve implantation and a positive trend was found in SAVR patients. We found no statistically significant differences between the quality of life of TAVI patients with regard to transfemoral or transapical approaches. MR et al. as a preplanned substudy of the PARTNER trial 12 . The patients were randomized into TAVI using the Sapien valve or conservative treatment. TAVI patients improved significantly more than the conservative patients at 1 and 12 months, as assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the SF-12 QoL questionnaires.
More information is available for the patients treated surgically. Sedryakan et al. confirmed that age was not a limiting factor for quality of life improvement after cardiac valve surgery 13 . Later on they found similar quality of life results in 73 prospectively evaluated patients after both mechanical and tissue valve implants at 18 months and after adjustment for age and several risk factors 14 . In contrast with these data we found only a positive trend in general QoL improvement in the "bioprosthesis" SAVR group at one year.
To the best of our knowledge a comparison between SAVR and TAVI, from the beginning of treatment through 1 yr. follow-up in the same Cardiac Center has never been published.
Study limitation
Due to its focus on the population of the Czech Republic, the study was limited in sample size and hence statistical power. This fact was taken into consideration during the interpretation and discussion of statistical results. The study was not randomized but observational, and was based on a multi-disciplinary heart-team decision. The standardized EQ-5D (three level) questionnaire that was used in the study prevented direct comparisons with results from other authors using different scoring systems (KCCQ, SF-36 or SF-12). The mental status of the patients was not assessed.
